Today: 21 March 2026
Subscribe
Browse Category

Pharmaceuticals 18 December 2025 - 21 December 2025

Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

Eli Lilly shares closed at $1,071.44 on Friday, Dec. 19, up 4.3% from the previous week. The company’s stock remains near record highs as late-stage trial data showed its oral obesity drug orforglipron helped patients maintain weight loss after switching from injectables. Reuters reported the FDA is considering a faster review timeline for orforglipron.
21 December 2025
··
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals (RXRX) closed at $4.26 on December 19, 2025, with a market cap of about $2.1 billion after releasing Phase 1b/2 data for REC‑4881 in familial adenomatous polyposis. The trial showed a median 43% reduction in polyp burden at 13 weeks and 53% at 25 weeks. REC‑4881 has Fast Track and Orphan Drug status from the FDA and EU. Trading volume was heavy, with sentiment split on commercialization prospects.
21 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer shares closed at $25.19 on Dec. 19, down 4.7% from earlier in the week after the company issued 2026 guidance projecting flat or lower reported results. The company expects 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and loss of exclusivity. Market cap stands near $114 billion.
21 December 2025
··
AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie shares closed at $226.82 on Friday, up 1.8%, nearing a 52-week high with a market cap near $400 billion. U.S. drug pricing policy returned to focus after the Trump administration announced agreements with nine drugmakers, excluding AbbVie, which remains in upcoming negotiations. New Medicare pilot programs tied to international price referencing were also announced. Trading volume approached 19 million shares.
21 December 2025
··
Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

A Minnesota jury awarded $65.5 million to a plaintiff who said Johnson & Johnson’s talc products caused mesothelioma, with J&J vowing to appeal. JNJ shares last traded at $206.37, down 0.9% from the prior close and about 3.6% below their December 15 record. Over 67,000 plaintiffs are suing J&J over similar claims. The company declared a $1.30 quarterly dividend for Q4 2025.
20 December 2025
·
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly shares closed at $1,071.44 on Dec. 19, near record highs, after reporting positive Phase 3 results for its oral weight-loss drug orforglipron. The company also cut prices on Zepbound and Mounjaro in the U.S. and Canada. Lilly’s market value surpassed $1 trillion this year amid growing demand for obesity and cardiometabolic treatments.
20 December 2025
···
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals shares surged 11% on Dec. 17 after JPMorgan upgraded the stock, then retreated to close at $4.26 on Dec. 19 as trading volume spiked. The moves followed positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis, showing a median 43% reduction in polyp burden at 13 weeks. Most adverse events were mild or moderate.
20 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer shares closed at $25.19 after a volatile week marked by a sharp selloff following new 2026 guidance. The company forecasted 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, with COVID-19 product sales expected to drop further. Management signaled no return to revenue growth until 2029, citing patent expirations and pricing pressures.
20 December 2025
···
Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals closed up 1.97% at $456.20 Friday, ending a three-day slide on volume of about 5.56 million shares, far above its 50-day average. After-hours trading was quiet, with the stock quoted near $456.49 as of 7:40 p.m. ET. No major company news drove the move; trading reflected broad market gains and heavy year-end positioning.
20 December 2025
··
Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences shares jumped 2.3% to $124.29 Friday after the company announced a three-year U.S. drug pricing deal tied to TrumpRx.gov and tariff relief, plus new U.K. approval for lenacapavir. Trading volume spiked to 24.39 million shares. After-hours, the stock edged up to $124.78. The White House said Epclusa’s U.S. price will drop from $24,920 to $2,425 under the new agreement.
20 December 2025
··
Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck shares closed at $101.09 Friday, up 0.4%, then dipped slightly after hours as investors reacted to new U.S. drug-pricing agreements and FDA acceleration for two pipeline drugs. Trading volume surged to 43.6 million shares after the Trump administration and major pharma firms, including Merck, finalized deals to cut drug prices and grant tariff relief.
20 December 2025
··
Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly shares closed at $1,071.44 on Friday, Dec. 19, up 1.38%, then edged up just 0.08% after hours. The move followed Phase 3 trial results showing orforglipron, Lilly’s oral GLP-1 drug, helped maintain weight loss after injectable therapies. Lilly confirmed FDA submission for obesity treatment. Expedited review could bring a decision by March 2026.
20 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer shares closed at $25.37 on Dec. 19, 2025, up 1.3% with volume near 43.5 million. The company forecast 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and patent expirations as key drags. Investors tracked a positive bladder cancer trial and new U.S. drug-pricing rules affecting Pfizer’s portfolio.
19 December 2025
··
Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025

Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025

Olema Pharmaceuticals (OLMA) fell 6.2% to $28.89 intraday Friday on Nasdaq, after opening at $31.22 and swinging between $31.95 and $28.89. No new company news was released; the move follows heightened volatility since Roche’s positive Phase 3 SERD data in November and Olema’s $190 million public offering.
19 December 2025
···
Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

Merck shares rose modestly Thursday after BMO Capital Markets upgraded the stock to Outperform and raised its price target to $130. The FDA is reportedly moving to fast-track two Merck pipeline drugs. Merck also announced positive Phase 3 results for Keytruda plus Padcev in earlier-stage bladder cancer, showing improved survival outcomes.
18 December 2025
··
Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next

Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next

Terns Pharmaceuticals shares fell to $39.62 on Dec. 18 after opening near $42.55, following weeks of sharp gains driven by positive TERN-701 trial data in chronic myeloid leukemia. The company reported a 74% major molecular response rate at 24 weeks in its Phase 1 trial and selected doses for Phase 2 expansion. Trading volume topped 2 million shares.
18 December 2025
··
Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals shares fell about 8% Thursday after a regulatory filing disclosed Chief Medical and Development Officer Dr. Dana Pizzuti will step down December 31. She will transition to a Strategic Regulatory and Development Advisor role in early 2026. The stock traded in the low-to-high $40s as investors reacted to the leadership change.
18 December 2025
·
Eli Lilly (LLY) Stock News Today: Orforglipron Pill Data, Pricing Moves, and Wall Street Forecasts for 2026

Eli Lilly (LLY) Stock News Today: Orforglipron Pill Data, Pricing Moves, and Wall Street Forecasts for 2026

Eli Lilly reported positive Phase 3 results for its oral obesity drug orforglipron, showing patients maintained prior weight loss after switching from injectable treatments. Shares rose about 1.75% to $1,060 on Thursday. The company also plans significant price cuts for Mounjaro and Zepbound in Canada, according to a separate report. Lilly said orforglipron’s safety profile matched earlier studies, with mostly mild gastrointestinal side effects.
18 December 2025
··
1 … 23 24 25 26 27 … 38

Stock Market Today

  • TD1.AX TALi Digital plunges 16.67% amid liquidity concerns and sector weakness
    March 20, 2026, 11:34 PM EDT. TD1.AX shares of TALi Digital Limited fell 16.67% intraday to A$0.04 on March 21, 2026, marking significant losses for the small-cap healthcare tech stock. Trading volume hit 67,918 shares, below average, highlighting limited liquidity and sharp price swings. The company's earnings report shows ongoing losses with an EPS of -0.02 and weak revenue growth, intensifying investor concerns amid a pressured ASX healthcare sector. Financial ratios indicate a stable liquidity cushion but stretched receivables and negative free cash flow point to operational risks. Technical indicators reveal the stock is oversold, with forecasts suggesting potential upside of up to 66% over 12 months, though risks persist given thin trading and negative margins.
Go toTop